Since the comprehensive recommendations for the management of acute promyelocytic
leukemia (APL) reported in 2009, several studies have provided important insights …

Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML)
that is cytogenetically characterized by a balanced reciprocal translocation between …

Poor efficiency of chemotherapeutics in the eradication of Cancer Stem Cells (CSCs) has
been driving the search for more active and specific compounds. In this work, we show how …

The outcome of patients with acute promyelocytic leukaemia (APL) has dramatically
improved over the last two decades, due to the introduction of combined all‐trans retinoic …

Pediatric acute promyelocytic leukemia (APL) can be cured with all-trans retinoic acid
(ATRA) and anthracycline. However, most published trials have employed high cumulative …

The introduction of all-trans retinoic acid combined with anthracyclines has significantly
improved the outcomes for patients diagnosed with acute promyelocytic leukemia (APL) …

By combining the analysis of mutations with aberrant expression of genes previously related
to poorer prognosis in both acute promyelocytic leukemia (APL) and acute myeloid …

The introduction of all-trans retinoic acid combined with anthracyclines has significantly
improved the outcomes for patients diagnosed with acute promyelocytic leukemia (APL) …

Introduction Patients with acute promyelocytic leukemia (APL) are characterized by the
highest expression of Wilms' tumor 1 (WT1) gene compared with other subtypes of acute …

Approximately one third of patients diagnosed with acute promyelocytic leukemia (APL) are
above the age of sixty. It is important to ensure older adults receive optimal diagnosis and …